RNS Number : 1085L Incanthera PLC 11 December 2025

RNS 编号：1085L Incanthera PLC2025年12月11日

11 December 2025

2025年12月11日

Incanthera plc

("Incanthera", the "Company" or "Group")

（"Incanthera"、"公司"或"集团"）

HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

截至2025年9月30日的半年业绩

Incanthera plc, the company focused on innovative technologies in dermatology and oncology, presents its interim results for the six months ended 30 September 2025.

Incanthera plc 是一家专注于皮肤病学和肿瘤学创新技术的公司，现发布截至2025年9月30日的中期业绩。

Highlights

亮点

· Launch of Skin+Cell via Direct To Consumer (DTC) route through dedicated website.

· 通过专门网站推出 Skin+Cell 直接面向消费者（DTC）渠道。

· Investment in establishment of DTC infrastructure and promotional activities.

· 投资建立 DTC 基础设施和推广活动。

· Proactive discussions and activities directed at additional routes to market.

· 积极进行讨论和活动，寻求其他市场渠道。

Simon Ward, CEO, commented:

首席执行官 Simon Ward 评论道：

"This period has seen the launch of our Skin+CELL skincare range launched globally via our dedicated Direct To Consumer ("DTC") website www.skinandcell.com. Establishing any new brand into a marketplace takes time, however, since launch, we have seen steady increases month on month, in traction across social media, hits to our website and conversion to sales. This is recognised in the positive feedback we have received from all users of the product range, unanimous in its praise on the dramatic effects on their skin, across all demographics.

"这一时期，我们的 Skin+CELL 护肤系列通过专门的直接面向消费者（"DTC"）网站 www.skinandcell.com 在全球推出。建立任何新品牌进入市场需要时间，但自推出以来，我们在社交媒体上的关注度、网站访问量和销售转化率每月稳步增长。这在我们收到的所有用户的积极反馈中得到了认可，大家一致赞扬其对皮肤的显著效果，涵盖所有人群。

We have previously advised that we are actively exploring additional routes to market, alongside the DTC route. Discussions are progressing with a number of parties on potential collaborations and deals.

我们之前已告知，我们正在积极探索除了 DTC 渠道之外的其他市场渠道。与多方的讨论正在进行中，探讨潜在的合作和交易。

We look forward to updating the market further on these activities."

我们期待进一步向市场更新这些活动的进展。"

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

本公告包含根据英国市场滥用法规的内幕信息，公司董事对本公告的发布负责。

For further information please contact:

如需更多信息，请联系：


Incanthera plc www.incanthera.com Tim McCarthy, Chairman tim.mccarthy@incanthera.com Simon Ward, Chief Executive Officer simon.ward@incanthera.com Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com	+44 (0) 7831 675747 +44 (0) 7747 625506 +44 (0) 7776 234600
Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes	+44 (0) 20 7213 0880
Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney	+44 (0) 20 3650 3650/51


Incanthera plc www.incanthera.com Tim McCarthy, 主席 tim.mccarthy@incanthera.com Simon Ward, 首席执行官 simon.ward@incanthera.com Suzanne Brocks, 传播负责人 suzanne.brocks@incanthera.com	+44 (0) 7831 675747 +44 (0) 7747 625506 +44 (0) 7776 234600
Aquis 交易所企业顾问： Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes	+44 (0) 20 7213 0880
经纪人： Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney	+44 (0) 20 3650 3650/51

Notes to Editors

编辑注释

About Incanthera plc

关于 Incanthera plc

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

Incanthera 是一家专注于皮肤病学和肿瘤学创新技术的专业公司。它旨在识别和开发针对当前临床上、商业上相关的未满足需求的创新解决方案，利用来自领先专家和学术机构的新技术，以及其内部开发团队。

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

该公司起源于布拉德福德大学的癌症治疗研究所（"ICT"）。Incanthera 的战略是将其投资组合中的每个候选产品从初始收购或发现阶段发展到通过商业上有价值的合作伙伴关系在其开发路径的最早机会确保其未来。

For more information on the Company please visit: www.incanthera.com

有关公司的更多信息，请访问：www.incanthera.com

@incantheraplc

About Skin + CELL

关于 Skin + CELL

Skin + CELL is Incanthera's luxury skincare brand utilising our ground-breaking formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge pharmaceutical enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.

Skin + CELL 是 Incanthera 的奢华护肤品牌，利用我们突破性的配方和交付专业知识，将科学证明的配方带入化妆品。Skin + CELL 的互补产品系列基于先进的、临床设计的配方浓缩物，结合尖端的药物增强技术与精选的高端化妆品成分，提供有效的产品，使用时具有丝滑的润肤感，使皮肤看起来光彩照人、充满活力并得到保护。

Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.

Incanthera 的新型生物活性护肤技术由我们内部专家开发，他们曾为一些全球领先的护肤和制药公司配制外用产品。这些配方强化了本来被削弱的生理通路，以改善皮肤的表现、自我修复能力，并解决皮肤健康中先前未满足的美容问题。

Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.

Skin + CELL 的奢华护肤系列目前涵盖面部、身体、手部、面部精华和眼霜，未来还将包括生物活性防晒浓缩物和更多维生素衍生物。

Forward looking statement disclaimer

前瞻性声明免责声明

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

本公告中所作的某些声明为前瞻性声明。这些前瞻性声明不是历史事实，而是基于公司当前的期望、估计和对其行业的预测；其信念；和假设。诸如 “预期”、“期望”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语旨在识别前瞻性声明。这些声明并不保证未来的表现，并且受到已知和未知的风险、不确定性和其他因素的影响，其中一些超出了公司的控制，难以预测，可能导致实际结果与前瞻性声明中表达或预测的结果有重大差异。公司提醒股东和潜在股东不要对这些前瞻性声明过于依赖，这些声明仅反映公司在本公告日期的观点。公告中所作的前瞻性声明仅与声明作出之日的事件相关。除法律或任何适当监管机构要求外，公司将不承担公开发布任何修订或更新这些前瞻性声明以反映公告日期后发生的事件、情况或意外事件的义务。

Incanthera plc

HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

截至2025年9月30日的半年业绩

CEO's Report

首席执行官报告

This period has seen the launch of our Skin+CELL skincare range launched globally via our dedicated Direct To Consumer ("DTC") website www.skinandcell.com and through social media platforms of Instagram, FaceBook and TikTok.

这一时期，我们的 Skin+CELL 护肤系列通过专门的直接面向消费者（"DTC"）网站 www.skinandcell.com 以及 Instagram、Facebook 和 TikTok 等社交媒体平台在全球推出。

Skin+CELL is a unique product. It is a luxury skincare range, which has been created by scientific experts in formulation and delivery technologies and is uniquely capable of effecting cellular repair. The products are aesthetically stunning in look and feel and have demonstrated proven results backed by our own and independent scientific research.

Skin+CELL 是一款独特的产品。它是一系列奢华护肤品，由科学专家在配方和传递技术方面创造，独特地能够实现细胞修复。这些产品在外观和触感上都令人惊艳，并且通过我们自己的研究和独立的科学研究证明了其有效性。

That effect is recognised in the positive feedback we have received from all users of the product range, unanimous in its praise on the dramatic effects on their skin, across all demographics.

这种效果在我们收到的所有用户的积极反馈中得到了认可，用户一致赞扬其对皮肤的显著效果，涵盖所有人群。

Establishing any new brand into a marketplace takes time, however, we have seen good initial traction across social media and positive feedback through our website from those consumers who have purchased Skin+CELL with immediate revenues recorded in the six weeks from our August launch to the end of September reporting period.

在市场上建立任何新品牌都需要时间，然而，我们在社交媒体上看到了良好的初步反响，并且从购买 Skin+CELL 的消费者那里通过我们的网站收到了积极反馈，在从八月发布到九月底的六周内记录了即时收入。

We have also seen recent (post balance sheet) sales volumes increasing due to sales and promotions, including a B3Face cream discount and a Black Friday event. This is also influenced by increased traction across social media, hits to our website and subsequent conversion to sales.

我们还看到最近（资产负债表后）由于销售和促销，销售量有所增加，包括 B3Face 面霜的折扣和黑色星期五活动。这也受到社交媒体上增加的关注、我们网站的访问量以及随后的销售转化的影响。

We have looked at the specific data, which is an invaluable asset, owned by us, to understand from where hits to our site are directed, which product is most popular and location/demographic of the purchaser. The data shows that our most successful marketing is via Instagram and our most successful product is B3 Face.

我们查看了具体数据，这是一项无价的资产，由我们拥有，以了解我们网站的访问来源、最受欢迎的产品以及购买者的地点/人群。数据表明，我们最成功的营销渠道是 Instagram，而我们最成功的产品是 B3 Face。

As well as analysing the data from the website, we are collating feedback from consumers on our launch and subsequent roll out. Our next steps are to enhance and amplify the DTC global roll out and look further to brand expansion and innovation.

除了分析网站的数据外，我们还在收集消费者对我们发布和后续推广的反馈。我们的下一步是增强和扩大 DTC 全球推广，并进一步考虑品牌扩展和创新。

Scientific research published in June demonstrates Skin+CELL's unique capabilities, providing independent proof of our technology and firmly underlining the repairing, restoring and positive protective effects of our formulation to bring a unique new approach to skincare, including valuable UV protection data.

2023 年 6 月发布的科学研究证明了 Skin+CELL 的独特能力，提供了我们技术的独立证据，坚定地强调了我们的配方在修复、恢复和积极保护方面的效果，为护肤带来了独特的新方法，包括有价值的紫外线保护数据。

Skincare that is scientifically proven to reach below the dermal layer to the cellular structure, to effect real change in restoration and repair truly is skincare for everyone.

经过科学验证的护肤品能够深入真皮层，影响细胞结构，真正实现修复和恢复的变化，确实是每个人都适用的护肤品。

我们之前已告知，我们正在积极探索除了 DTC 渠道之外的其他市场途径。与多方的潜在合作和交易的讨论正在进行中。

We look forward to updating the market further on these activities.

我们期待进一步向市场更新这些活动的进展。

Dr Simon Ward

西蒙·沃德博士

Chief Executive Officer

首席执行官

11 December 2025

2025年12月11日

Incanthera plc

HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

截至2025年9月30日的半年度业绩

Consolidated Statement of Comprehensive Income

综合收益表

for the six months ended 30 September 2025 - unaudited

截至2025年9月30日的六个月 - 未经审计


		Six months ended 30 September 2025	Six months ended 30 September 2024	Year ended 31 March 2025
		Unaudited	Unaudited	Audited
	Notes	£'000	£'000	£'000
Revenue		6	-	-
Cost of Sales		(1)	-	-
Gross Profit		5	-	-
Direct Costs		(90)	-	-
Operating expenses
Operating expenses		(760)	(654)	(1,783)
Share based compensation	4	(43)	(41)	(214)
Total operating expenses		(893)	(695)	(1,997)
Operating loss		(888)	(695)	(1,997)
Loss on ordinary activities before taxation		(888)	(695)	(1,997)
Other Income		-	75	-
Taxation		-	-	-
Loss and total comprehensive expense attributable to equity holders of the parent for the year	(888)	(620)	(1,997)
Loss per share attributable to equity holders of the parent (pence)
Basic loss per share		(0.69)	(0.57)	(1.77)
Diluted loss per share		(0.69)	(0.57)	(1.77)


		截至2025年9月30日的六个月	截至2024年9月30日的六个月	截至2025年3月31日的年度
		未经审计	未经审计	已审计
	备注	£'000	£'000	£'000
收入		6	-	-
销售成本		(1)	-	-
毛利润		5	-	-
直接成本		(90)	-	-
营业费用
营业费用		(760)	(654)	(1,783)
基于股份的补偿	4	(43)	(41)	(214)
总营业费用		(893)	(695)	(1,997)
营业亏损		(888)	(695)	(1,997)
税前普通活动亏损		(888)	(695)	(1,997)
其他收入		-	75	-
税务		-	-	-
归属于母公司股东的亏损和总综合费用	(888)	(620)	(1,997)
归属于母公司股东的每股亏损（便士）
基本每股亏损		(0.69)	(0.57)	(1.77)
稀释每股亏损		(0.69)	(0.57)	(1.77)

Consolidated Statement of Financial Position

综合财务状况表

as at 30 September 2025 - unaudited

截至2025年9月30日- 未经审计


		Group	Group	Group
		As at	As at	As at
		30 September 2025	30 September 2024	31 March 2025
		Unaudited	Unaudited	Audited
	Notes	£'000	£'000	£'000
ASSETS
Non-current assets
Property, plant and equipment		3	3	3
Intangible assets		7	57	7
Investments in subsidiary undertaking		-	-	-
Total non-current assets		10	60	10
Current assets
Trade and other receivables		595	52	741
Inventory and WIP		868	1,236	869
Current tax receivable		1	-	-
Cash and cash equivalents		215	1,058	80
Total current assets		1,679	2,346	1,690
Total assets		1,689	2,406	1,700
LIABILITIES AND EQUITY
Current liabilities
Trade and other payables		933	505	547
Total current liabilities		933	505	547
Non-current Liabilities
Convertible loan		-	-	-
Total Liabilities		933	505	547
Equity
Ordinary shares	5	2,758	2,338	2,427
Share premium		9,020	8,505	8,903
Reorganisation reserve		2,715	2,715	2,715
Currency Translation reserve		-	(2)	-
Warrant reserve		1,321	1,185	1,294
Other reserves		-	-	-
Share based compensation		407	360	391
Retained deficit		(15,465)	(13,200)	(14,577)
Total equity attributable to equity holders of the parent		756	1,901	1,153
Total liabilities and equity		1,689	2,406	1,700


		集团	集团	集团
		截至	截至	截至
		2025年9月30日	2024年9月30日	2025年3月31日
		未经审计	未经审计	已审计
	备注	£'000	£'000	£'000
资产
非流动资产
房产、厂房和设备		3	3	3
无形资产		7	57	7
对子公司的投资		-	-	-
总非流动资产		10	60	10
流动资产
应收账款及其他应收款		595	52	741
存货和在制品		868	1,236	869
应收当前税款		1	-	-
现金及现金等价物		215	1,058	80
总流动资产		1,679	2,346	1,690
总资产		1,689	2,406	1,700
负债和股东权益
流动负债
应付账款及其他应付款		933	505	547
总流动负债		933	505	547
非流动负债
可转换贷款		-	-	-
总负债		933	505	547
股东权益
普通股	5	2,758	2,338	2,427
股本溢价		9,020	8,505	8,903
重组准备金		2,715	2,715	2,715
汇率转换准备金		-	(2)	-
权证准备金		1,321	1,185	1,294
其他准备金		-	-	-
基于股份的补偿		407	360	391
留存亏损		(15,465)	(13,200)	(14,577)
归属于母公司股东的总权益		756	1,901	1,153
总负债和股东权益		1,689	2,406	1,700

Consolidated Statement of Changes in Equity

综合权益变动表

for the six months ended 30 September 2025 - unaudited

截至2025年9月30日的六个月 - 未经审计


	Share capital	Share premium	Merger reserve	Warrant reserve	Share based compensation	Currency translation reserve	Accumulated losses	Total
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Balance at 1 April 2025	2,427	8,903	2,715	1,294	391	-	(14,577)	1,153
Total comprehensive expense for the period	-	-	-	-	-	-	(888)	(888)
Transactions with owners
Share issue - investment July 2025	331	117	-	-	-	-	-	448
Share-based compensation - share options	-	-	-	27	16	-	-	43
Total transactions with owners	331	117	-	27	16	-	-	491
Balance at 30 September 2025	2,758	9,020	2,715	1,321	407	-	(15,465)	756


	股本	股本溢价	合并储备	权证储备	基于股份的补偿	货币转换储备	累计亏损	总计
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
2025年4月1日的余额	2,427	8,903	2,715	1,294	391	-	(14,577)	1,153
本期的综合费用总额	-	-	-	-	-	-	(888)	(888)
与所有者的交易
股份发行 - 投资 2025 年 7 月	331	117	-	-	-	-	-	448
基于股份的补偿 - 股票期权	-	-	-	27	16	-	-	43
与所有者的交易总额	331	117	-	27	16	-	-	491
2025年9月30日的余额	2,758	9,020	2,715	1,321	407	-	(15,465)	756


	Share capital	Share premium	Merger reserve	Warrant reserve	Share based compensation	Currency translation reserve	Accumulated losses	Total
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Balance at 1 April 2024	1,842	5,954	2,715	1,185	319	-	(12,580)	(565)
Total comprehensive expense for the period	-	-	-	-	-	(2)	(620)	(622)
Transactions with owners
Share issue - warrant exercise	148	584	-	-	-	-	-	732
Share issue - cash	348	1,967	-	-	-	-	-	2,315
Share-based compensation - share options	-	-	-	-	41	-	-	41
Total transactions with owners	496	2,551	-	-	41	-	-	3,088
Balance at 30 September 2024	2,338	8,505	2,715	1,185	360	(2)	(13,200)	1,901


	股本	股本溢价	合并储备	权证储备	基于股份的补偿	货币转换储备	累计亏损	总计
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
2024年4月1日的余额	1,842	5,954	2,715	1,185	319	-	(12,580)	(565)
本期的综合费用总额	-	-	-	-	-	(2)	(620)	(622)
与所有者的交易
股份发行 - 权证行使	148	584	-	-	-	-	-	732
股份发行 - 现金	348	1,967	-	-	-	-	-	2,315
基于股份的补偿 - 股票期权	-	-	-	-	41	-	-	41
与所有者的交易总额	496	2,551	-	-	41	-	-	3,088
2024年9月30日的余额	2,338	8,505	2,715	1,185	360	(2)	(13,200)	1,901


	Share capital	Share premium	Merger reserve	Warrant reserve	Share based compensation	Currency translation reserve	Accumulated losses	Total
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Balance at 1 April 2024	1,842	5,954	2,715	1,185	319	-	(12,580)	(565)
Total comprehensive expense for the period	-	-	-	-	-	-	(1,997)	(1,997)
Transactions with owners
Share issue - in lieu of creditors	89	291	-	-	-	-	-	380
Share issue - warrant exercise	148	551	-	-	-	-	-	699
Share issue - investment Jun 24	348	1,999	-	-	-	-	-	2,347
Warrant extension fee received	-	-	-	75	-	-	-	75
Share-based compensation - share options	-	108	-	34	72	-	-	214
Total transactions with owners	585	2,949	-	109	75	-	-	3,715
Balance at 31 March 2025	2,427	8,903	2,715	1,294	391	-	(14,577)	1,153


	股本	股本溢价	合并储备	权证储备	基于股份的补偿	货币转换储备	累计亏损	总计
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
2024年4月1日的余额	1,842	5,954	2,715	1,185	319	-	(12,580)	(565)
本期的综合费用总额	-	-	-	-	-	-	(1,997)	(1,997)
与所有者的交易
股份发行 - 以偿还债务	89	291	-	-	-	-	-	380
股份发行 - 权证行使	148	551	-	-	-	-	-	699
股份发行 - 投资 2024 年 6 月	348	1,999	-	-	-	-	-	2,347
权证延期费用收入	-	-	-	75	-	-	-	75
基于股份的补偿 - 股票期权	-	108	-	34	72	-	-	214
与所有者的交易总额	585	2,949	-	109	75	-	-	3,715
2025年3月31日的余额	2,427	8,903	2,715	1,294	391	-	(14,577)	1,153

The registered number of Incanthera plc is 11026926.

Incanthera plc 的注册号码是 11026926。

Consolidated Statement of Cash Flows

合并现金流量表

for the six months ended 30 September 2025 - unaudited

截至2025年9月30日的六个月 - 未经审计


	Group	Group	Group
	Six months ended 30 September 2025	Six months ended 30 September 2024	Year ended 31 March 2025
	Unaudited	Unaudited	Audited
	£'000	£'000	£'000
Cash flows from operating activities
Loss before taxation	(888)	(620)	(1,997)
Depreciation and amortisation	-	1	58
Currency Translation difference	-	(2)	-
Share based compensation	43	41	214
	(845)	(580)	(1,725)
Changes in working capital
(Increase)/decrease in trade and other receivables	146	(8)	(697)
(Increase)/decrease in inventories and WIP	1	(1,236)	(869)
Increase/(decrease) in trade and other payables	386	(226)	196
Creditor Swap
Cash used in operations	533	(1,470)	(1,370)
Taxation received	(1)	-	-
Net cash used in operating activities	(313)	(2,050)	(3,095)
Cash flows (used in)/generated from investing activities
Acquisition of tangible fixed assets	-	-	(7)
Net cash (used in)/generated from investing activities	-	-	(7)
Cash flows from financing activities
Proceeds from warrant extension	-	-	75
Proceeds from issue of shares	580	3,342	3,342
Issue costs	(132)	(295)	(296)
Net cash generated from financing activities	448	3,047	3,121
Movements in cash and cash equivalents in the period	135	997	19
Cash and cash equivalents at start of period	80	61	61
Cash and cash equivalents at end of period	215	1,058	80


	集团	集团	集团
	截至2025年9月30日的六个月	截至2024年9月30日的六个月	截至2025年3月31日的年度
	未经审计	未经审计	已审计
	£'000	£'000	£'000
来自经营活动的现金流
税前亏损	(888)	(620)	(1,997)
折旧和摊销	-	1	58
货币转换差额	-	(2)	-
基于股份的补偿	43	41	214
	(845)	(580)	(1,725)
营运资金的变动
应收账款的（增加）/减少	146	(8)	(697)
存货和在制品的（增加）/减少	1	(1,236)	(869)
应付账款的增加/(减少)	386	(226)	196
债权人互换
经营活动中使用的现金	533	(1,470)	(1,370)
收到的税款	(1)	-	-
经营活动中使用的净现金	(313)	(2,050)	(3,095)
投资活动中的现金流（使用）/产生
固定资产的购置	-	-	(7)
投资活动中使用的/产生的净现金	-	-	(7)
融资活动中的现金流
权证延期的收入	-	-	75
股份发行的收入	580	3,342	3,342
发行费用	(132)	(295)	(296)
融资活动中产生的净现金	448	3,047	3,121
期间现金及现金等价物的变动	135	997	19
期初现金及现金等价物	80	61	61
期末现金及现金等价物	215	1,058	80

1. GENERAL INFORMATION

1. 一般信息

Incanthera plc ('the Company') is a public limited company incorporated in England and Wales and was admitted to trading on the AQSE Growth Market, under the symbol INC on 28 February 2020. The Company trades on the Apex segment.

Incanthera plc（“公司”）是一家在英格兰和威尔士注册的公众有限公司，并于2020年2月28日以 INC 为交易代码在 AQSE 增长市场上市。该公司在 Apex 板块交易。

The address of its registered office is c/o Gateley plc, Ship Canal House, 98 King Street, Manchester, England, M2 4WU and the registered company number is 11026926. The principal activity of the Company is clinical stage drug development.

其注册办公地址为：c/o Gateley plc, Ship Canal House, 98 King Street, Manchester, England, M2 4WU，注册公司号码为 11026926。公司的主要活动是临床阶段药物开发。

2. BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES

2. 编制基础和重要会计政策

Basis of preparation

编制基础

The consolidated financial statements have been prepared in accordance with UK adopted International Financial Accounting Standards ('IFRS'), IFRIC interpretations and the Companies Act 2006 applicable to companies operating under IFRS.

合并财务报表已根据英国采纳的国际财务会计准则（“IFRS”）、IFRIC 解释和适用于在 IFRS 下运营公司的 2006 年公司法编制。

The consolidated financial statements are presented in Sterling (£) and rounded to the nearest £'000. This is the predominant functional currency of the Group and is the currency of the primary economic environment in which it operates.

合并财务报表以英镑（£）呈现，并四舍五入到最接近的£'000。这是集团的主要功能货币，也是其运营的主要经济环境的货币。

The consolidated financial statements have not been reviewed by the Group's auditors.

合并财务报表未经过集团审计师的审查。

3. LOSS PER SHARE

3. 每股亏损

Basic loss per share is calculated by dividing the loss for the period attributable to equity holders by the weighted average number of ordinary shares outstanding during the period.

基本每股亏损是通过将归属于股东的期间亏损除以期间内流通在外的普通股加权平均数来计算的。

For diluted loss per share, the loss for the period attributable to equity holders and the weighted average number of ordinary shares outstanding during the period is adjusted to assume conversion of all dilutive potential ordinary shares. As the effect of the share options would be to reduce the loss per share, the diluted loss per share is the same as the basic loss per share.

对于稀释每股亏损，归属于股东的期间亏损和期间内流通在外的普通股加权平均数会进行调整，以假设所有可稀释潜在普通股的转换。由于股票期权的影响会减少每股亏损，因此稀释每股亏损与基本每股亏损相同。

The calculation of the Group's basic and diluted loss per share is based on the following data:

集团基本和稀释每股亏损的计算基于以下数据：


	Six months ended 30 September 2025	Six months ended 30 September 2024	Year ended 31 March 2025
	£'000	£'000	£'000
	Unaudited	unaudited	Audited
Loss for the period attributable to equity holders for basic loss and adjusted for the effects of dilution	(888)	(620)	(1,997)
	As at 30 September 2025	As at 30 September 2024	As at 31 March 2024
	Number	Number	Number
	Unaudited	Unaudited	Audited
Weighted average number of ordinary shares	129,166,801	108,378,872	112,595,162
Weighted average number of ordinary shares adjusted for the effects of dilution	129,166,801	108,378,872	112,595,162
	Pence	Pence	Pence
Loss per share - basic and diluted	(0.69)	(0.57)	(1.77)


	截至2025年9月30日的六个月	截至2024年9月30日的六个月	截至2025年3月31日的年度
	£'000	£'000	£'000
	未审计	未审计	已审计
归属于股东的期间亏损（基本亏损和稀释影响调整后）	(888)	(620)	(1,997)
	截至 2025年9月30日	截至 2024年9月30日	截至 2024年3月31日
	数量	数量	数量
	未审计	未审计	已审计
普通股加权平均数	129,166,801	108,378,872	112,595,162
考虑稀释影响的普通股加权平均数	129,166,801	108,378,872	112,595,162
	便士	便士	便士
每股亏损 - 基本和稀释	(0.69)	(0.57)	(1.77)

4. SHARE-BASED PAYMENTS

4. 基于股份的支付

As at the end of the current period, the reconciliation of share option scheme movements is as follows:

截至当前期间末，股票期权计划变动的对账如下：


	As at 30 September 2025
	Number	WAEP Pence
Outstanding at 1 April 2025	8,975,000	10.77
Granted during the period	-	-
Exercised during the period	-	-
Lapsed/cancelled during the period	-	-
Outstanding at 30 September 2025	8,975,000	10.77


	截至2025年9月30日
	数量	WAEP 便士
2025年4月1日的未行使	8,975,000	10.77
期间内授予	-	-
期间内行使	-	-
期间内失效/取消	-	-
截至2025年9月30日的未行使	8,975,000	10.77

During the six month period ended 30 September 2025, a share-based payment charge of £43,073 (2024: £41,126) was expensed to the consolidated Statement of Comprehensive Income.

在截至2025年9月30日的六个月期间，基于股份的支付费用为£43,073（2024 年：£41,126），已计入合并综合收益表。

The fair values of the options granted have been calculated using a Black-Scholes model.

授予的期权的公允价值是使用 Black-Scholes 模型计算的。

5. ISSUED CAPITAL AND RESERVES

5. 已发行资本和储备

Ordinary shares

普通股


	Company
	Number of Shares	Share Capital (£'000)
At 31 March 2025	121,366,645	2,427
Issued on placing	16,571,429	331
At 30 September 2025	137,938,074	2,758


	公司
	股份数量	股本 (£'000)
截至2025年3月31日	121,366,645	2,427
发行于配售	16,571,429	331
截至2025年9月30日	137,938,074	2,758

New shares were issued during six-month period ended 30 September 2025 in relation to a placing agreement.

在截至2025年9月30日的六个月期间，因配售协议而发行了新股。

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NEXTBBMTMTMBMTA

RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动，并将此类分析以匿名方式与他人共享，作为我们商业服务的一部分。如需了解 RNS 和伦敦证券交易所如何使用您提供的个人数据，请参见我们的隐私政策。结束 NEXTBBMTMTMBMTA

公告 - Incanthera PLC - 半年度报告